BIOGRAPHICAL SKETCH

Provide the following information for the proposed network coordinators and members
Follow this format for each person.
NAME
Hugo ten Cate, MD PhD
(9-3-1958) / POSITION TITLE
Professor of Clinical Thrombosis and Haemostasis and PI, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, and include postdoctoral training.)
INSTITUTION AND LOCATION / DEGREE
(if applicable) / YEAR(s) / FIELD OF STUDY
University of Amsterdam, 1987, Medicine.
University of Amsterdam, 1987
Division of Hematology-Oncology, Beth Israel Hospital, Harvard Medical School, Boston, USA
Slotervaarthospital and Academic Medical Center (AMC), Amsterdam, 1996.
Laboratory for Experimental Internal Medicine, AMC, 1996-2002.
Laboratory Clinical Thrombosis and Hemostasis, Maastricht University Medical center and Cardiovascular Research Institute Maastricht, 2002-
Center for Clinical Thrombosis and Haemostasis, Gutenberg University Medical Center, Mainz
BIG nr: 99020447901
GCP: April 2014. / MD
PhD
PostDoc
Specialist Int medicine
Assistant professor
Full Professor
Professor (Fellow on behalf of the Gutenberg Research Foundation) / 1987
1987
1989
1996
1999
2001
2013 / Medicine
Medicine
Hemostasis and Thrombosis
Internal medicine
Internal medicine
Thrombosis and Hemostasis
Clinical Thrombosis and Hemostasis

A.  Positions and Honors (chronological order)

Positions: Internist-vascular medicine and Professor in Internal medicine, Clinical Thrombosis and Hemostasis,Maastricht University Medical Center; head: Maastricht Anticoagulation Clinic.

Chairman of the board, Dutch Federation of Anticoagulation clinics (FNT; 2011-), Member-elect, Council on Thrombosis of the International Society for Thrombosis and Haemostasis (ISTH) (2009-2014), Chairman of the PR & Communications committee of the ISTH (2010-2014). Co-chairman of the Animal Models committee of the ISTH- Scientific SubCommittee. Fellow American Heart Foundation, Member American Society of Hematology. Editorial board: Journal of Thrombosis and Haemostasis, Dataset Papers in Medicine, World Science Journal. Academic Editor, PlosOne. Section editor Thrombosis and Haemostasis; Editor-in-chief (jointly with dr. Yukio Ozaki) Thrombosis Journal.

Honors: Clinical Established Investigatorship, Netherlands Heart Foundation (1996-2002); Gutenberg Research Fellow, Johannes Gutenberg University Mainz, Germany, 2012.

B.  Most important recent publications

1: Borissoff J, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011; May 5;364(18):1746-60.

2: Borissoff JI, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers K, Govers-Riemslag JW, Hamulyák K, Hackeng TM, Daemen MJ, ten Cate H, Spronk HM. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010; 122(8):821-30.

3. Konings J, Govers-Riemslag J, Philippou H, Mutch N, Borissoff J, Allen P, Sumitra, Tans G, ten Cate H, Ariens RA. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011;118(14):3942-51. Epub 2011 Aug 9.

4: Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A. Intrinsic coagulation activation and the risk of arterial thrombosis in young women:results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation. 2010;122(18):1854-61.

5: Loubele ST, Spek CA, Leenders P, van Oerle R, Aberson HL, Hamulyák K, Ferrell G, Esmon CT, Spronk HM, ten Cate H. Activated protein C protects against myocardial ischemia/ reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol. 2009;29(7):1087-92.

C.  Current and anticipated grant support (total volume ~2 million €) - CTMM InnovativeCOagulationDiagnostics (INCOAG) 1.045.000.Mechanisms of particulate matter induced thrombogenicity. -Thrombosis Expertise Center; Annadal foundation.The impact of coagulation factor XII on mechanisms of thrombosis in patients with cardiovascular disease (NHF). -Mechanisms of particulate matter induced thrombogenicity (NHF)-Working mechanisms of activated protein C in a mouse model for myocardial ischemia/reperfusion injury (Thrombosis Foundation)-Characterization of the hemostatic profile of circulating blood cells in hematological malignancies at high risk of thrombosis (Profileringsfund)-Registry on Atrial Fibrillation, Thrombosis Research Institute, London

D.  Previous experience in collaborative research

Project leader CTMM InnovativeCOagulationDiagnostics (INCOAG),national multicenter program.

PI national CAVA multicenter study on thrombolysis for DVT

Project leader on program of cancer and thrombosis related studies with Ospedale Reuniti, Bergamo, Italy (dr. A. Falanga, co-project leader).

Collaborative research projects with drs. Robert Ariens, Leeds, UK; Charles T Esmon, Oklahoma, USA; Thomas Renne, Karolinska Institutet, Sweden;

PHS 398/2590 (Rev. 11/07) Page Continuation Format Page